A new treatment option for depression is offered at Marpa Minds in Suffern, where patients can receive FDA-approved Spravato, also known as esketamine, in a clinical setting.
For the past year, a Rockland County woman named Raizel has been receiving the treatment and says it has made a significant difference in her life.
"It really did change my life," Raizel said.
The treatment is administered as a nasal spray and is intended for people who have not found success with other antidepressants.
Raizel described the experience and how she believes it has helped her.
"The way it works it opens a different level on consciousness in your brain. It helps you process things in a new way," she said.
During a visit to Marpa Minds, Raizel showed what a typical treatment session looks like using a tester nasal spray.
A double-blind study published in JAMA Psychiatry last year found that esketamine reduced depression symptoms.
According to the study, patients who received esketamine showed improvement after 24 hours and 28 days, compared with those who received a placebo.
Amy Della Rocca, a psychiatrist with Marpa Minds, said the medication has produced results unlike those she has seen with other depression treatments.
"I've never seen results like this with depression. It's really been a game changing medication," Della Rocca said.
Della Rocca also addressed concerns about esketamine because it is another form of the drug ketamine.
"In this setting, safety is primary, that's our real focus and attention. So, we have very positive results," she said.
Potential serious side effects of the treatment include sedation and dissociation.
Patients remain at the clinic for a couple of hours after receiving the medication while providers monitor them.
Marpa Minds opened in Suffern in August and also has a White Plains location.